Adult: For the treatment of bronchopulmonary diseases associated with abnormal mucus secretion and clearance: As immediate-release preparation: 60-120 mg daily in 2-3 divided doses. As slow-release (retard) cap: 75 mg once daily. As 15 mg loz: Suck up to 6 loz daily (Max: 2 loz per dose). Seek medical advice if symptoms persist for more than 14 days. Child: As immediate-release preparation: 2-5 years 7.5-15 mg tid; 6-12 years 15-30 mg bid or tid; ≥12 years Same as adult dose. As 15 mg loz: 6-12 years Suck 1 loz tid.
What are the brands available for Ambroxol in Indonesia?
Patient with history of peptic ulceration. Renal and hepatic impairment. Treatment with a cough medicine in children should be considered carefully due to potential risks and limited evidence on efficacy. Pregnancy and lactation.
May increase the concentrations of antibiotics (e.g. amoxicillin, cefuroxime, erythromycin).
Lab Interference
May give false-positive results for lysergic acid diethylamide (LSD) using cloned enzyme donor immunoassay technology for drugs of abuse in urine (CEDIA DAU).
Action
Description: Mechanism of Action: Ambroxol is a mucolytic agent that increases respiratory tract secretion by enhancing the production of pulmonary surfactants and stimulating ciliary activity. This results in the improvement of mucociliary clearance and enhancement of fluid secretion which facilitates expectoration and eases cough. Onset: Rapid (loz); within 2 hours (oral solution and syr). Duration: ≥3 hours (loz). Pharmacokinetics: Absorption: Rapidly and completely absorbed (immediate-release). Bioavailability: 79% (immediate-release); 95% (slow-release). Time to peak plasma concentration: 1-2.5 hours (immediate-release); 6.5 hours (slow-release). Distribution: Rapid and pronounced distribution into body tissues with the highest concentration in the lungs. Crosses the placenta and enters breast milk. Volume of distribution: Approx 552 L. Plasma protein binding: Approx 90%. Metabolism: Mainly metabolised in the liver via glucuronidation by CYP3A4 and some cleavage into dibromanthranilic acid and minor metabolites; undergoes first-pass metabolism. Excretion: Mainly via urine (approx 83%). Elimination half-life: Approx 10 hours.
Chemical Structure
Ambroxol Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2132, Ambroxol. https://pubchem.ncbi.nlm.nih.gov/compound/Ambroxol. Accessed Mar. 28, 2023.
Sign Out
